Novartis Foundation healthcare models and disease elimination programs showcased at ECTMIH
(Thomson Reuters ONE) -
Novartis International AG /
Novartis Foundation healthcare models and disease elimination programs showcased
at ECTMIH
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* Telemedicine pilot in rural Ghana demonstrated positive impact and improved
primary health services as reported by nurses, midwives and patients
* Retrospective contact tracing of former leprosy patients in Cambodia was
effective in reducing disability of new patients through earlier diagnosis
* Electronic supportive supervision of healthcare professionals in Tanzania
helped to identify major quality gaps and showed quick improvements in
skills
* First mobile phone-facilitated leprosy detection system helps identify
patients in remote areas of the Philippines
Basel, September 7, 2015 - The Novartis Foundation and its partners will
highlight progress towards transforming the health of the poorest populations at
the 9(th) European Congress on Tropical Medicine and International Health
(ECTMIH) held in Basel from September 6 - 10. Updates on nine Novartis
Foundation-sponsored healthcare delivery models and disease elimination programs
in low- and middle-income countries will be showcased in scientific sessions and
sponsored-symposia.
"The ECTMIH is a great opportunity to join with our partners and the global
health community to review the progress we are making in the innovation of
healthcare delivery and disease elimination. It's an exciting time for us as we
are seeing projects such as Telemedicine in Ghana move towards scale and
integration into the local health system as well as new projects, such as our
leprosy contact tracing strategy, begin to gain momentum," said Dr. Ann Aerts,
Head of the Novartis Foundation.
Novartis Foundation-sponsored projects presented at ECTMIH scientific sessions:
* Identifying and addressing structural gaps in primary health care in
Tanzania (Abstract 1390, September 7, 15:30 CET)
* Ghana telemedicine - using mHealth to bridge the gaps in health service and
availability and accessibility (Abstract 218, September 8, 15:30 CET)
* Cambodia retrospective contact tracing project: innovation in contact
tracing to improve early diagnosis of leprosy (Abstract 773, September
9, 10:30 CET)
* Leprosy alert response network and surveillance system (LEARNS): Iloilo
implementation (Abstract 570, September 9, 10:30 CET)
* Evaluation of a community based program for hypertension control in Ghana
(Abstract 610, September 9, 12:15 CET)
* Public-private partnerships to strengthen human resources for health through
training and eLearning: a case study from Tanzania (Abstract 1018, September
9, 12:15)
Novartis-sponsored symposia at ECTMIH
* On the road to malaria elimination: where we have come from and what
challenges lie ahead? (September 7, 12:00) Co-sponsored by the Novartis
Malaria Initiative, the Novartis Institute for Tropical Disease and the
Novartis Foundation
* Digital Health on the Ground (September 8, 17:00) Sponsored by the Novartis
Foundation
Added Ann Aerts, "Our objective at ECTMIH is to share our learnings, the
successes and challenges, with the global health community and in turn, learn as
much as we can from them for our own work. We need to be open and collaborative
as we are all aiming towards the same goal to transform the health of the
poorest populations."
About the Novartis Foundation
The Novartis Foundation is a philanthropic organization pioneering innovative
healthcare models that can have a transformational impact on the health of the
poorest populations. We work hand-in-hand with our local and global partners to
catalyze scalable and sustainable healthcare models to improve access and health
outcomes, and to accelerate efforts to eliminate leprosy and malaria by focusing
on interventions that aim to interrupt transmission. Everything we do is
grounded in evidence and innovation, and our work is a continuous cycle of
evaluation, adaptation and application. In 2014, the operational budget for the
foundation was CHF 12 million and our programs reached 3.6 million people.
For more information, please visit:
www.novartisfoundation.org
www.youtube.com/novartisfoundation
Novartis Foundation is on Twitter. Sign up to follow (at)NovartisFDN at
https://twitter.com/NovartisFDN
Novartis Tropical Disease
Novartis is committed to combatting tropical diseases such as malaria, dengue
fever and leprosy, which continue to have a devastating effect on millions of
people living in under privileged areas of the world. We do this with innovative
research at the Novartis Institute for Tropical Diseases (NITD) in Singapore,
where our scientists use the latest techniques to discover next generation
treatments for some of these conditions. At the same time, we are working to
control and eliminate these diseases by improving access to treatments through
our Malaria Initiative and pioneering innovative healthcare models through the
Novartis Foundation. Since 2001, the Malaria Initiative has delivered more than
700 million antimalarial treatments to patients without profit, contributing to
a significant reduction of the death toll from malaria. The Novartis Foundation
works to accelerate efforts to eliminate leprosy and malaria by focusing on
interventions that aim to interrupt transmission. Novartis has also worked with
the World Health Organization (WHO) to provide free multidrug therapy (MDT) to
leprosy patients globally since 2000. Learn more about our efforts at
https://www.novartis.com/about-us/corporate-responsibility/access-healthcare
Disclaimer
This press release contains expressed or implied forward-looking statements,
including statements that can be identified by terminology such as "pilot,"
"will," "opportunity," "exciting," "move towards," "strategy," "begin,"
"objective," "aiming," "goal," "can," "focusing on," "aim," "continuous,"
"committed," "continue," "working to," "pioneering," "works to," "efforts," or
similar expressions. Such forward-looking statements reflect the current views
of the Group regarding future events, and involve known and unknown risks,
uncertainties and other factors that may cause actual results to be materially
different from any future results expressed or implied by such statements. These
expectations could be affected by, among other things, risks and factors
referred to in the Risk Factors section of Novartis AG's current Form 20-F on
file with the US Securities and Exchange Commission. Novartis is providing the
information in this press release as of this date and does not undertake any
obligation to update it in the future.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care and cost-saving generic pharmaceuticals. Novartis is the only global
company with leading positions in these areas. In 2014, the Group achieved net
sales of USD 58.0 billion, while R&D throughout the Group amounted to
approximately USD 9.9 billion (USD 9.6 billion excluding impairment and
amortization charges). Novartis Group companies employ approximately 120,000
full-time-equivalent associates. Novartis products are available in more than
180 countries around the world. For more information, please
visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis
at http://twitter.com/novartis.
# # #
Novartis Media Relations
Central media line : +41 61 324 2200
Eric Althoff Julie Morrow
Novartis Global Media Relations Novartis Foundation
+41 61 324 7999 (direct) +41 61 696 2421 (direct)
+41 79 593 4202 (mobile) +41 79 224 5666 (mobile)
eric.althoff(at)novartis.com julie.morrow(at)novartis.com
e-mail: media.relations(at)novartis.com
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact:
journalisthelp(at)thenewsmarket.com.
Novartis Investor Relations
Central phone: +41 61 324 7944
Samir Shah +41 61 324 7944 North
America:
Pierre-Michel +41 61 324 1065 Richard +1 212 830 2448
Bringer Pulik
Thomas +41 61 324 8425 Sloan +1 212 830 2417
Hungerbuehler Pavsner
Isabella Zinck +41 61 324 7188
e-mail: investor.relations(at)novartis.com e-
mail: investor.relations(at)novartis.com
Media release (PDF):
http://hugin.info/134323/R/1949716/708691.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novartis International AG via GlobeNewswire
[HUG#1949716]
Unternehmensinformation / Kurzprofil:
Datum: 07.09.2015 - 07:15 Uhr
Sprache: Deutsch
News-ID 418250
Anzahl Zeichen: 10710
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 236 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis Foundation healthcare models and disease elimination programs showcased at ECTMIH"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
